First demonstration of leukemia imaging with the proliferation marker 18F-fluorodeoxythymidine

Journal of Nuclear Medicine

Volumn 49, Issue 11, 2008, Pages 1756-1762

  Buck, Andreas K ^a,d   Bommer, Martin ^a   Juweid, Malik E ^b,c   Glatting, Gerhard ^a   Stilgenbauer, Stephan ^a   Mottaghy, Felix M ^a   Schulz, Melanie ^a   Kull, Thomas ^a   Bunjes, Donald ^a   Möller, Peter ^a   Döhner, Hartmut ^a   Reske, Sven N ^a  

^a UNIVERSITY OF ULM   (Germany)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Acute myeloid leukemia; Nucleoside analogs; Positron emission tomography; Proliferation

Indexed keywords

FLUORODEOXYTHYMIDINE F 18; TRACER; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BONE MARROW; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; CYTODIAGNOSIS; DRUG DISTRIBUTION; DRUG UPTAKE; FEMALE; HEMATOPOIETIC STEM CELL; HUMAN; MALE; PRIORITY JOURNAL;

ADULT; AGED; BONE MARROW; CASE-CONTROL STUDIES; CELL PROLIFERATION; DIDEOXYNUCLEOSIDES; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; TISSUE DISTRIBUTION; YOUNG ADULT;

EID: 57349094421     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.108.055335     Document Type: Article

References (36)

1. Estey E, Dohner H. Acute myeloid leukaemia. Lancet. 2006;368:1894-1907.
2. Kwee TC, Kwee RM, Nievelstein RA. Imaging in staging of malignant lymphoma: a systematic review. Blood. 2008;111:504-516.
3. Yildirim I, Uckan D, Cetin M, Tuncer M, Tezcan I. Isolated testicular and bone relapse in children with acute myeloblastic leukemia and chronic graft versus host disease after allogeneic BMT. Turk J Pediatr. 2007;49:206-209.
4. Owonikoko T, Agha M, Balassanian R, Smith R, Raptis A. Gemtuzumab therapy for isolated extramedullary AML relapse following allogeneic stem-cell transplant. Nat Clin Pract Oncol. 2007;4:491-495.
5. Kobayashi R, Tawa A, Hanada R, Horibe K, Tsuchida M, Tsukimoto I. Extramedullary infiltration at diagnosis and prognosis in children with acute myelogenous leukemia. Pediatr Blood Cancer. 2007;48:393-398.
6. Kikushige Y, Takase K, Sata K, et al. Repeated relapses of acute myelogenous leukemia in the isolated extramedullary sites following allogeneic bone marrow transplantations. Intern Med. 2007;46:1011-1014.
7. Potenza L, Luppi M, Riva G, et al. Isolated extramedullary relapse after autologous bone marrow transplantation for acute myeloid leukemia: case report and review of the literature. Am J Hematol. 2006;81:45-50.
8. Bromberg JE, Breems DA, Kraan J, et al. CSF flow cytometry greatly improves diagnostic accuracy in CNS hematologic malignancies. Neurology. 2007;68:1674-1679.
9. Juweid ME, Cheson BD. Positron-emission tomography and assessment of cancer therapy. N Engl J Med. 2006;354:496-507.
10. Seam P, Juweid ME, Cheson BD. The role of FDG-PET scans in patients with lymphoma. Blood. 2007;110:3507-3516.
11. 18F]-fluoro-D-glucose. Mol Imaging Biol. 2002;4:179-183.
12. 11C]thymidine positron emission tomography in advanced intra-abdominal malignancies. Cancer Res. 2002;62:5698-5702.
13. Martiat P, Ferrant A, Labar D, et al. In vivo measurement of carbon-11 thymidine uptake in non-Hodgkin's lymphoma using positron emission tomography. J Nucl Med. 1988;29:1633-1637.
14. 18F]FLT and positron emission tomography. Nat Med. 1998;4:1334-1336.
15. Buck AK, Bommer M, Stilgenbauer S, et al. Molecular imaging of proliferation in malignant lymphoma. Cancer Res. 2006;66:11055-11061.
16. 18F-FLT PET in hematologic disorders: a novel technique to analyze the bone marrow compartment. J Nucl Med. 2006;47:1592-1598.
17. 123I-ITdU-mediated nanoirradiation of DNA efficiently induces cell kill in HL60 leukemia cells and in doxorubicin-, beta-, or gamma-radiation-resistant cell lines. J Nucl Med. 2007;48:1000-1007.
18. Jaffe ES, Harris NL, Stein H. World Health Organization: classification of tumours - pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2001.
19. 18F]FLT). J Radioanal Nucl Chem. 2000;24:843-846.
20. 18F]fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules. Cancer Res. 2002;62:3331-3334.
21. Schmidlin P. Improved iterative image reconstruction using variable projection binning and abbreviated convolution. Eur J Nucl Med. 1994;21:930-936.
22. Rasey JS, Grierson JR, Wiens LW, Kolb PD, Schwartz JL. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med. 2002;43:1210-1217.
23. 18F]FLT) as positron emission tomography tracer for imaging proliferation in a murine B-cell lymphoma model and in the human disease. Cancer Res. 2003;63:2681-2687.
24. 11C-methylmethionine as markers of increased transport and proliferation in brain tumors. J Nucl Med. 2005;46:1948-1958.
25. Jahns-Streubel G, Reuter C, Auf der Landwehr U, et al. Activity of thymidine kinase and of polymerase alpha as well as activity and gene expression of deoxycytidine deaminase in leukemic blasts are correlated with clinical response in the setting of granulocyte-macrophage colony-stimulating factor-based priming before and during TAD-9 induction therapy in acute myeloid leukemia. Blood. 1997;90:1968-1976.
26. O'Neill KL, Zhang F, Li H, Fuja DG, Murray BK. Thymidine kinase 1: a prognostic and diagnostic indicator in ALL and AML patients. Leukemia. 2007;21:560-563.
27. Wiley JS, Snook MB, Jamieson GP. Nucleoside transport in acute leukaemia and lymphoma: close relation to proliferative rate. Br J Haematol. 1989;71:203-207.
28. 18F]FLT. Eur J Nucl Med Mol Imaging. 2007;34:1775-1782.
29. 18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res. 2003;63:3791-3798.
30. 18F]fluorothymidine positron emission tomography: the effect of cisplatin on a fibrosarcoma tumor model in vivo. Cancer Res. 2005;65:4202-4210.
31. 18F]fluorothymidine-positron emission tomography in high-grade non-Hodgkin's lymphoma. Clin Cancer Res. 2007;13:3552-3558.
32. 18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol. 2007;25:4714-4721.
33. 18]fluoro-3′-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. Mol Imaging Biol. 2006;8:36-42.
34. Galmarini CM, Mackey JR, Dumontet C. Nucleoside analogues and nucleobases in cancer treatment. Lancet Oncol. 2002;3:415-424.
35. 18F]fluorothymidine into L5178Y tumours in vivo is dependent on thymidine kinase 1 protein levels. Eur J Nucl Med Mol Imaging. 2005;32:257-263.
36. Perumal M, Pillai RG, Barthel H, et al. Redistribution of nucleoside transporters to the cell membrane provides a novel approach for imaging thymidylate synthase inhibition by positron emission tomography. Cancer Res. 2006;66:8558-8564.